OmniAb Inc. (OABI)
| Bid | 1.86 |
| Market Cap | 228.71M |
| Revenue (ttm) | 26.39M |
| Net Income (ttm) | -62.03M |
| EPS (ttm) | -0.61 |
| PE Ratio (ttm) | -3.1 |
| Forward PE | -3.86 |
| Analyst | Buy |
| Ask | 1.92 |
| Volume | 668,763 |
| Avg. Volume (20D) | 698,639 |
| Open | 1.91 |
| Previous Close | 1.93 |
| Day's Range | 1.86 - 1.94 |
| 52-Week Range | 1.81 - 4.97 |
| Beta | 0.80 |
About OABI
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been geneti...
Analyst Forecast
According to 3 analyst ratings, the average rating for OABI stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 217.46% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
OmniAb to Report Fourth Quarter 2024 Financial Results on March 18EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Tues...
